InflaRx (NASDAQ:IFRX) Sees Significant Growth in Short Interest

InflaRx (NASDAQ:IFRX) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 248,900 shares, an increase of 15.0% from the December 31st total of 216,500 shares. Based on an average trading volume of 264,900 shares, the days-to-cover ratio is currently 0.9 days.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a research note on Thursday, January 16th.

InflaRx Stock Up 1.7 %

NASDAQ IFRX opened at $2.41 on Monday. The company’s 50 day moving average is $2.40 and its 200-day moving average is $1.85. InflaRx has a 12-month low of $1.16 and a 12-month high of $2.82. The firm has a market cap of $141.90 million, a P/E ratio of -2.23 and a beta of 1.66.

InflaRx (NASDAQ:IFRX) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.06). InflaRx had a negative net margin of 33,362.70% and a negative return on equity of 65.98%. The business had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.05 million. During the same period last year, the firm earned ($0.14) EPS. Equities analysts expect that InflaRx will post -1.04 EPS for the current year.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.